Total: $200.069M

Company

Location

Amt. (M)

Details

Date


Alder BioPharmaceuticals Inc.

Bothell, Wash.

$38

Alder raised $38M in a Series D round led by new investor Novo Ventures; other investors were Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech

4/20/12

AlloCure Inc.

Burlington, Mass.

$25

AlloCure raised $25M for a Series B venture financing with Lundbeckfond Ventures, SV Life Sciences and Novo A/S

4/3/12

Argos Therapeutics Inc.

Durham, N.C.

$25

Argos raised $25M in a Series D round led by Forbion Capital; other investors were TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement du Quebec, Morningside Group and Aurora Funds

4/25/12

BioRelix Inc.

New Haven, Conn.

$0.269

BioRelix received a follow-on investment of $269,160 from Connecticut Innovations, which is part of a $2.5M funding round

4/4/12

Cerecor Inc.

Baltimore

$22

Cerecor raised more than $22M in an overallotment of a Series A preferred stock financing

4/5/12

Galenea Corp.

Cambridge, Mass.

$6

Galenea got a $6M equity investment from the Stanley Medical Research Institute

4/27/12

Imaxio SA

Lyon, France

€2.9 ($3.8)

Imaxio raised $3.8M from principal shareholder Pradeyrol Developpement

4/18/12

Innovacell Biotechnologie AG

Innsbruck, Austria

€8.3 ($11)

Innovacell raised $11M in two tranches; main shareholders are Buschier, Fides, HYBAG and uni venture

4/27/12

miRagen Therapeutics Inc.

Boulder, Colo.

$20

miRagen raised $20M in a Series B round led by Remeditex Ventures LLC; other investors were Atlas Venture, Boulder Ventures Ltd., Amgen Ventures and Broadview Ventures

4/25/12

Oligomerix Inc.

New York

$2

Oligomerix raised $2M in a Series A funding; lead investors were Wheatley MedTech Partners LP, Wheatley New York Partners LP and Durand Venture Associates LLC

4/24/12

OvaScience

Cambridge, Mass.

$37

OvaScience raised $37M in a Series B financing led by General Catalyst; existing investors Bessemer Venture Partners and Longwood Fund were joined in the round by new investors BBT Capital Management Advisors LLC, Cycad Group, Hunt BioVentures, RA Capital and an undisclosed global institutional investor

4/5/12

Tioga Pharmaceuticals Inc.

San Diego

$10

Tioga closed a $10M Series B round led by Thomas, McNerney & Partners, which invested $8M in the round; Genesys Capital Partners also participated

4/13/12


Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed.